FI871139A0 - Antitumoermedel. - Google Patents

Antitumoermedel.

Info

Publication number
FI871139A0
FI871139A0 FI871139A FI871139A FI871139A0 FI 871139 A0 FI871139 A0 FI 871139A0 FI 871139 A FI871139 A FI 871139A FI 871139 A FI871139 A FI 871139A FI 871139 A0 FI871139 A0 FI 871139A0
Authority
FI
Finland
Prior art keywords
antitumoermedel
Prior art date
Application number
FI871139A
Other languages
English (en)
Other versions
FI89912B (fi
FI871139A (fi
FI89912C (fi
Inventor
Leslie Richard Hughes
Original Assignee
Ici Plc
Nat Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Plc, Nat Res Dev filed Critical Ici Plc
Publication of FI871139A0 publication Critical patent/FI871139A0/fi
Publication of FI871139A publication Critical patent/FI871139A/fi
Publication of FI89912B publication Critical patent/FI89912B/fi
Application granted granted Critical
Publication of FI89912C publication Critical patent/FI89912C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI871139A 1986-03-27 1987-03-16 Foerfarande foer framstaellning av terapeutiskt anvaendbara kinazolinderivat FI89912C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8607683 1986-03-27
GB868607683A GB8607683D0 (en) 1986-03-27 1986-03-27 Anti-tumor agents

Publications (4)

Publication Number Publication Date
FI871139A0 true FI871139A0 (fi) 1987-03-16
FI871139A FI871139A (fi) 1987-09-28
FI89912B FI89912B (fi) 1993-08-31
FI89912C FI89912C (fi) 1993-12-10

Family

ID=10595358

Family Applications (1)

Application Number Title Priority Date Filing Date
FI871139A FI89912C (fi) 1986-03-27 1987-03-16 Foerfarande foer framstaellning av terapeutiskt anvaendbara kinazolinderivat

Country Status (22)

Country Link
US (2) US4992550A (fi)
EP (1) EP0239362B1 (fi)
JP (1) JPH0657699B2 (fi)
AR (1) AR244213A1 (fi)
AT (1) ATE70057T1 (fi)
AU (1) AU592628B2 (fi)
CA (1) CA1285943C (fi)
DE (1) DE3774909D1 (fi)
DK (1) DK166621B1 (fi)
ES (1) ES2038170T3 (fi)
FI (1) FI89912C (fi)
GB (2) GB8607683D0 (fi)
GR (1) GR3003282T3 (fi)
HK (1) HK8594A (fi)
HU (1) HU197317B (fi)
IE (1) IE60302B1 (fi)
IL (1) IL81924A (fi)
LU (1) LU88797I2 (fi)
NL (1) NL970024I2 (fi)
NO (2) NO173545C (fi)
PT (1) PT84571B (fi)
ZA (1) ZA871998B (fi)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8513754D0 (en) * 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
GB8625019D0 (en) * 1986-10-18 1986-11-19 Wellcome Found Compounds
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4857530A (en) * 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
GB8727737D0 (en) * 1987-11-26 1987-12-31 Ici Plc Antitumour agents
US4940713A (en) * 1988-04-15 1990-07-10 Burroughs Wellcome Co. Substituted glutamic acids
US5019577A (en) * 1988-04-15 1991-05-28 Burroughs Welcome Co. Novel compounds and use
GB8809978D0 (en) * 1988-04-27 1988-06-02 Ici Plc Anti-tumour agents
EP0365763A1 (en) * 1988-09-30 1990-05-02 Agouron Pharmaceuticals, Inc. Antiproliferative cyclic compounds
US5252573A (en) * 1988-12-15 1993-10-12 Imperial Chemical Industries Plc Anti-tumor agents
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
US5286726A (en) * 1990-04-12 1994-02-15 The Regents Of The University Of Michigan Difluoroglutamic acid conjugates with folates and anti-folates for the treatment of neoplastic diseases
AU640016B2 (en) * 1990-05-30 1993-08-12 Imperial Chemical Industries Plc Hydroquinazoline derivatives
GB9013615D0 (en) * 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
US5290780A (en) * 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
GB9105771D0 (en) * 1991-03-19 1991-05-01 Cancer Res Inst Royal Anti-cancer compounds
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
EP0530537B1 (en) * 1991-08-12 1997-01-08 Takeda Chemical Industries, Ltd. Condensed pyrimidine derivatives, their production and use as antitumor agents
US5145854A (en) * 1991-11-27 1992-09-08 Nair Madhavan G 1-formyl-5,8,10-trideazafolates
GB9205320D0 (en) * 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
GB9205907D0 (en) * 1992-03-18 1992-04-29 Cancer Res Inst Royal Anti-cancer compounds
ES2049659B1 (es) * 1992-10-08 1994-10-16 Ici Plc Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.
GB9223352D0 (en) * 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US7910624B1 (en) 1995-03-03 2011-03-22 The Trustees Of Boston University Compositions for the treatment of blood disorders
AU696167B2 (en) * 1993-10-29 1998-09-03 Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5593999A (en) * 1995-06-07 1997-01-14 Nair; Madhavan G. Non-classical folate analogue inhibitors of glycinamide ribonucleotide formyltransferase (GARFT)
US6420427B1 (en) * 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
US5912251A (en) * 1998-01-17 1999-06-15 Nair; Madhavan G. Metabolically inert anti-inflammatory and anti-tumor antifolates
WO1999040883A2 (en) * 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
GB9904275D0 (en) 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6143776A (en) * 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
ATE483722T1 (de) 2001-08-31 2010-10-15 Btg Int Ltd Antikrebs-cyclopentaag chinazoline-derivate
ES2373644T3 (es) 2001-08-31 2012-02-07 Btg International Limited Uso de derivados de ciclopenta[g]quinazolina para el tratamiento del c�?ncer.
US6753428B2 (en) * 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
US7009049B2 (en) * 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
ES2335276T3 (es) 2002-03-13 2010-03-24 Array Biopharma, Inc. Derivados de bencimidazol alquilado n3 como inhibidores de mek.
EP1553931A4 (en) 2002-05-09 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1503993A4 (en) * 2002-05-09 2006-05-03 Cytokinetics Inc COMPOUNDS, METHODS AND COMPOSITIONS
WO2003103575A2 (en) * 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005538062A (ja) * 2002-06-14 2005-12-15 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
WO2004018058A2 (en) * 2002-08-21 2004-03-04 Cytokinetics, Inc. Compounds, compositions, and methods
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
US7557115B2 (en) * 2002-09-30 2009-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
DK1625121T3 (da) 2002-12-20 2010-05-10 Pfizer Prod Inc Pyrimidinderivater til behandling af abnorm cellevækst
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US20050197327A1 (en) * 2003-11-03 2005-09-08 Gustave Bergnes Compounds, compositions, and methods
JP2007510660A (ja) * 2003-11-07 2007-04-26 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
MXPA06005657A (es) 2003-11-19 2006-08-23 Array Biopharma Inc Inhibidores heterociclicos de mek y metodos para usarlos.
WO2005061460A1 (en) * 2003-12-08 2005-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
JP4842929B2 (ja) 2004-05-27 2011-12-21 ファイザー・プロダクツ・インク 癌治療に有用なピロロピリミジン誘導体
JP2008512490A (ja) 2004-09-08 2008-04-24 チェルシー・セラピューティクス，インコーポレイテッド 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
KR100990027B1 (ko) 2005-04-26 2010-10-26 화이자 인코포레이티드 Ｐ-카드헤린 항체
CN101626767A (zh) 2005-05-18 2010-01-13 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US7537762B2 (en) 2005-09-07 2009-05-26 Amgen Fremont, Inc. Human monoclonal antibodies to activin receptor-like kinase-1
WO2007121269A2 (en) 2006-04-11 2007-10-25 Ardea Biosciences, Inc. N-aryl-n'alkyl sulfamides as mek inhibitors
ATE483463T1 (de) 2006-04-18 2010-10-15 Ardea Biosciences Inc Pyridonsulfonamide und pyridonsulfamide als mek- hemmer
EP2021338A1 (en) 2006-05-09 2009-02-11 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
AU2008206161A1 (en) 2007-01-19 2008-07-24 Chelsea Therapeutics, Inc. New classical antifolates
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
US8673919B2 (en) 2009-03-27 2014-03-18 Ardea Biosciences, Inc. Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors
NZ597107A (en) 2009-06-25 2013-12-20 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011027249A2 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
WO2011056957A2 (en) 2009-11-06 2011-05-12 Chelsea Therapeutics, Inc. Enzyme inhibiting compounds
WO2011068403A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts
CN102802412A (zh) 2009-12-08 2012-11-28 海玛奎斯特医药公司 用于治疗红细胞病症的方法及低剂量方案
WO2011084846A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Quaternary ammonium salt prodrugs
KR20120127495A (ko) 2010-02-12 2012-11-21 화이자 인코포레이티드 8-플루오로-2-｛4-［(메틸아미노)메틸］페닐｝-1,3,4,5-테트라하이드로-6ｈ-아제피노［5,4,3-ｃｄ］인돌-6-온의 염 및 다형체
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
WO2012028578A1 (de) 2010-09-03 2012-03-08 Bayer Cropscience Ag Substituierte anellierte pyrimidinone und dihydropyrimidinone
EP2630134B9 (en) 2010-10-20 2018-04-18 Pfizer Inc Pyridine-2- derivatives as smoothened receptor modulators
WO2012078708A1 (en) 2010-12-07 2012-06-14 Chelsea Therapeutics, Inc. Combination comprising methotrexate and an antifolate compound
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
EP2685979B1 (en) 2011-03-18 2016-08-24 Alkermes Pharma Ireland Limited Injectable pharmaceutical compositions comprising a water-insoluble anti-psychotic, sorbitan laurate and polysorbate 20
KR20140059246A (ko) 2011-09-22 2014-05-15 화이자 인코포레이티드 피롤로피리미딘 및 퓨린 유도체
CN102424679B (zh) * 2011-11-15 2014-07-30 扬子江药业集团有限公司 一种雷替曲塞的制备方法
EP2827866B1 (en) 2012-03-19 2023-05-03 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
WO2014080285A2 (en) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
KR20160058960A (ko) 2013-10-04 2016-05-25 압토스 바이오사이언시스 인코포레이티드 암을 치료하기 위한 조성물과 방법
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
US9452131B2 (en) 2014-03-20 2016-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
BR112016024513A2 (pt) 2014-04-30 2017-08-15 Pfizer derivados de di-heterociclo ligados à cicloalquila
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
EP3227279B1 (en) * 2014-12-02 2019-02-13 Eli Lilly and Company 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as aicarft inhibitors in the treatment of cancers
ES2746839T3 (es) 2014-12-18 2020-03-09 Pfizer Derivados de pirimidina y triazina y su uso como inhibidores de AXL
CN104447724B (zh) * 2014-12-31 2017-11-10 四川峨嵋山药业有限公司 一种雷替曲塞的精制方法
AU2016286091B2 (en) 2015-06-29 2021-02-04 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
US20190008869A1 (en) 2016-01-13 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of an Antifolate and a BTK Inhibitor
CN106957311B (zh) * 2016-12-29 2020-03-31 南京正大天晴制药有限公司 雷替曲塞的溶剂化物及其制备方法
CN106957312B (zh) * 2016-12-29 2019-11-01 南京正大天晴制药有限公司 雷替曲塞水合物晶型及其制备方法
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略
CN109734698B (zh) * 2019-01-25 2020-07-17 宏冠生物药业有限公司 一种雷替曲塞关键中间体的合成工艺
CN114206447A (zh) 2019-05-31 2022-03-18 维拉克塔附属公司 用组蛋白脱乙酰基酶抑制剂治疗病毒相关的癌症的方法
EP3986890B1 (en) 2019-06-18 2023-11-15 Pfizer Inc. Benzisoxazole sulfonamide derivatives
AU2020295006B2 (en) 2019-06-19 2023-11-09 Ctxt Pty Ltd Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1021196A (en) * 1964-02-20 1966-03-02 Parke Davis & Co Novel amino acids and means for producing the same
EP0031237B1 (en) * 1979-12-19 1984-10-17 National Research Development Corporation Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
GB8513754D0 (en) * 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives

Also Published As

Publication number Publication date
LU88797I2 (fr) 1996-11-05
US4992550A (en) 1991-02-12
ES2038170T3 (es) 1993-07-16
FI89912B (fi) 1993-08-31
NO173545B (no) 1993-09-20
NO871266L (no) 1987-09-28
AR244213A1 (es) 1993-10-29
DE3774909D1 (de) 1992-01-16
AU592628B2 (en) 1990-01-18
DK166621B1 (da) 1993-06-21
JPH0657699B2 (ja) 1994-08-03
JPH01125373A (ja) 1989-05-17
CA1285943C (en) 1991-07-09
HU197317B (en) 1989-03-28
IE60302B1 (en) 1994-06-29
HUT43835A (en) 1987-12-28
HK8594A (en) 1994-02-04
FI871139A (fi) 1987-09-28
IL81924A (en) 1991-07-18
GR3003282T3 (en) 1993-02-17
EP0239362A2 (en) 1987-09-30
DK155087D0 (da) 1987-03-26
ATE70057T1 (de) 1991-12-15
PT84571B (pt) 1989-11-30
IE870699L (en) 1987-09-27
AU7047287A (en) 1987-10-01
PT84571A (en) 1987-04-01
GB2188319A (en) 1987-09-30
ZA871998B (en) 1987-11-25
NL970024I2 (nl) 1997-10-01
GB8706948D0 (en) 1987-04-29
FI89912C (fi) 1993-12-10
NO1998020I1 (no) 1998-09-28
GB2188319B (en) 1989-12-13
EP0239362B1 (en) 1991-12-04
DK155087A (da) 1987-09-28
US5081124A (en) 1992-01-14
NO173545C (no) 1993-12-29
GB8607683D0 (en) 1986-04-30
EP0239362A3 (en) 1989-07-05
NO871266D0 (no) 1987-03-26
NL970024I1 (nl) 1997-09-01

Similar Documents

Publication Publication Date Title
ATE70057T1 (de) Antitumormittel.
DE3775679D1 (de) Vernebler.
DE3767169D1 (de) Sportschuh.
ES2019949B3 (es) Propanaminas 3-ariloxi-3-sustituidas.
DE3764043D1 (de) Alkylendiamine.
ATE63533T1 (de) Xylolisomerisierung.
DE3779761D1 (de) Abseilgeraet.
DE3771918D1 (de) Chinolinamide.
DE3785294D1 (de) Neigungsmesser.
DE3786679D1 (de) Schmitt-triggerschaltung.
DE3773636D1 (de) Saeurebeschleunigte hydrocarboxilierung.
DE3771271D1 (de) Fluorphthalimide.
FI860054A (fi) Motionsanordning.
DE3779382D1 (de) 3-6-diphenylpyridazine.
DE3763648D1 (de) Rollski.
FI860046A0 (fi) Foerlaengningsanordning foer traefaner.
DE3669032D1 (de) Okulopressionsgeraet.
DE3766410D1 (de) Methylalkylcyclosiloxane.
DE3770459D1 (de) 3-halogensuccinimide.
DE3764485D1 (de) Polyglycidylamine.
FI860072A (fi) Mataranordning foer en spannmaolstork.
FI851776L (fi) Elkandelaber.
FI77950B (fi) Foergreningsklaemma foer en sektorformig kapad huvudledning.
FI77951B (fi) Foergreningsklaemma foer en sektorformig stomledare.
ATE63902T1 (de) 3-halogensuccinimide.

Legal Events

Date Code Title Description
BB Publication of examined application
PC Transfer of assignment of patent

Owner name: ZENECA LIMITED

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L107

Extension date: 20100811

FG Patent granted

Owner name: ASTRAZENECA UK LIMITED

Owner name: NATIONAL RESEARCH DEVELOPMENT

MA Patent expired